vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and Metallus Inc. (MTUS). Click either name above to swap in a different company.
Metallus Inc. is the larger business by last-quarter revenue ($308.3M vs $281.3M, roughly 1.1× Guardant Health, Inc.). Metallus Inc. runs the higher net margin — 1.8% vs -45.7%, a 47.4% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 9.9%). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 2.3%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
GH vs MTUS — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $308.3M |
| Net Profit | $-128.5M | $5.4M |
| Gross Margin | 64.6% | 8.1% |
| Operating Margin | -43.0% | — |
| Net Margin | -45.7% | 1.8% |
| Revenue YoY | 39.4% | 9.9% |
| Net Profit YoY | -15.8% | 315.4% |
| EPS (diluted) | $-1.01 | $0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $308.3M | ||
| Q4 25 | $281.3M | $267.3M | ||
| Q3 25 | $265.2M | $305.9M | ||
| Q2 25 | $232.1M | $304.6M | ||
| Q1 25 | $203.5M | $280.5M | ||
| Q4 24 | $201.8M | $240.5M | ||
| Q3 24 | $191.5M | $227.2M | ||
| Q2 24 | $177.2M | $294.7M |
| Q1 26 | — | $5.4M | ||
| Q4 25 | $-128.5M | $-14.3M | ||
| Q3 25 | $-92.7M | $8.1M | ||
| Q2 25 | $-99.9M | $3.7M | ||
| Q1 25 | $-95.2M | $1.3M | ||
| Q4 24 | $-111.0M | $-21.4M | ||
| Q3 24 | $-107.8M | $-5.9M | ||
| Q2 24 | $-102.6M | $4.6M |
| Q1 26 | — | 8.1% | ||
| Q4 25 | 64.6% | 2.2% | ||
| Q3 25 | 64.7% | 11.4% | ||
| Q2 25 | 65.0% | 10.6% | ||
| Q1 25 | 63.3% | 7.8% | ||
| Q4 24 | 61.6% | 4.5% | ||
| Q3 24 | 61.1% | 5.3% | ||
| Q2 24 | 59.1% | 8.2% |
| Q1 26 | — | — | ||
| Q4 25 | -43.0% | -7.7% | ||
| Q3 25 | -37.3% | 3.6% | ||
| Q2 25 | -45.9% | 2.8% | ||
| Q1 25 | -54.6% | 1.0% | ||
| Q4 24 | -62.4% | -10.1% | ||
| Q3 24 | -61.3% | -3.1% | ||
| Q2 24 | -56.8% | 2.1% |
| Q1 26 | — | 1.8% | ||
| Q4 25 | -45.7% | -5.3% | ||
| Q3 25 | -35.0% | 2.6% | ||
| Q2 25 | -43.0% | 1.2% | ||
| Q1 25 | -46.8% | 0.5% | ||
| Q4 24 | -55.0% | -8.9% | ||
| Q3 24 | -56.3% | -2.6% | ||
| Q2 24 | -57.9% | 1.6% |
| Q1 26 | — | $0.13 | ||
| Q4 25 | $-1.01 | $-0.34 | ||
| Q3 25 | $-0.74 | $0.19 | ||
| Q2 25 | $-0.80 | $0.09 | ||
| Q1 25 | $-0.77 | $0.03 | ||
| Q4 24 | $-0.90 | $-0.46 | ||
| Q3 24 | $-0.88 | $-0.13 | ||
| Q2 24 | $-0.84 | $0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $104.0M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $683.0M |
| Total Assets | $2.0B | $1.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $104.0M | ||
| Q4 25 | $378.2M | $156.7M | ||
| Q3 25 | $580.0M | $191.5M | ||
| Q2 25 | $629.1M | $190.8M | ||
| Q1 25 | $698.6M | $180.3M | ||
| Q4 24 | $525.5M | $240.7M | ||
| Q3 24 | $585.0M | $254.6M | ||
| Q2 24 | $933.7M | $272.8M |
| Q1 26 | — | — | ||
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | $0 | ||
| Q2 25 | $1.1B | $0 | ||
| Q1 25 | $1.1B | $5.4M | ||
| Q4 24 | $1.1B | $5.4M | ||
| Q3 24 | — | $13.2M | ||
| Q2 24 | — | $13.2M |
| Q1 26 | — | $683.0M | ||
| Q4 25 | $-99.3M | $686.0M | ||
| Q3 25 | $-354.5M | $697.7M | ||
| Q2 25 | $-305.5M | $690.0M | ||
| Q1 25 | $-250.8M | $686.1M | ||
| Q4 24 | $-139.6M | $690.5M | ||
| Q3 24 | $-60.1M | $712.7M | ||
| Q2 24 | $-1.6M | $736.3M |
| Q1 26 | — | $1.1B | ||
| Q4 25 | $2.0B | $1.1B | ||
| Q3 25 | $1.3B | $1.2B | ||
| Q2 25 | $1.3B | $1.1B | ||
| Q1 25 | $1.3B | $1.1B | ||
| Q4 24 | $1.5B | $1.1B | ||
| Q3 24 | $1.5B | $1.1B | ||
| Q2 24 | $1.6B | $1.1B |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.00× | ||
| Q2 25 | — | 0.00× | ||
| Q1 25 | — | 0.01× | ||
| Q4 24 | — | 0.01× | ||
| Q3 24 | — | 0.02× | ||
| Q2 24 | — | 0.02× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | — |
| Free Cash FlowOCF − Capex | $-54.2M | — |
| FCF MarginFCF / Revenue | -19.3% | — |
| Capex IntensityCapex / Revenue | 9.9% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-26.4M | $-1.9M | ||
| Q3 25 | $-35.4M | $22.0M | ||
| Q2 25 | $-60.3M | $34.8M | ||
| Q1 25 | $-62.7M | $-38.9M | ||
| Q4 24 | $-64.5M | $13.9M | ||
| Q3 24 | $-51.1M | $-15.3M | ||
| Q2 24 | $-94.0M | $8.3M |
| Q1 26 | — | — | ||
| Q4 25 | $-54.2M | $-37.2M | ||
| Q3 25 | $-45.8M | $-6.4M | ||
| Q2 25 | $-65.9M | $17.0M | ||
| Q1 25 | $-67.1M | $-66.4M | ||
| Q4 24 | $-83.4M | $-1.3M | ||
| Q3 24 | $-55.3M | $-32.9M | ||
| Q2 24 | $-99.1M | $-5.8M |
| Q1 26 | — | — | ||
| Q4 25 | -19.3% | -13.9% | ||
| Q3 25 | -17.3% | -2.1% | ||
| Q2 25 | -28.4% | 5.6% | ||
| Q1 25 | -33.0% | -23.7% | ||
| Q4 24 | -41.3% | -0.5% | ||
| Q3 24 | -28.9% | -14.5% | ||
| Q2 24 | -55.9% | -2.0% |
| Q1 26 | — | 0.0% | ||
| Q4 25 | 9.9% | 13.2% | ||
| Q3 25 | 3.9% | 9.3% | ||
| Q2 25 | 2.4% | 5.8% | ||
| Q1 25 | 2.2% | 9.8% | ||
| Q4 24 | 9.4% | 6.3% | ||
| Q3 24 | 2.2% | 7.7% | ||
| Q2 24 | 2.9% | 4.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 2.72× | ||
| Q2 25 | — | 9.41× | ||
| Q1 25 | — | -29.92× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 1.80× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
MTUS
Segment breakdown not available.
